Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy

Abstract

We have been developing synthetic gene promoters responsive to clinical doses of ionizing radiation (IR) for use in suicide gene therapy vectors. The crucial DNA sequences utilized are units with the consensus motif CC(A/T)6GG, known as CArG elements, derived from the IR-responsive Egr1 gene. In this study we have investigated the parameters needed to enhance promoter activation to radiation. A series of plasmid vectors containing different enhancer/promoters were constructed, transiently transfected into tumor cells (MCF-7 breast adenocarcinoma and U-373MG glioblastoma) and expression of a downstream reporter assayed. Results revealed that increasing the number of CArG elements, up to a certain level, increased promoter radiation-response; from a fold-induction of 1.95 ± 0.17 for four elements to 2.74 ± 0.17 for nine CArGs of the same sequence (for MCF-7 cells). Specific alteration of the core A/T sequences caused an even greater positive response, with fold-inductions of 1.71 ± 0.23 for six elements of prototype sequence compared with 2.96 ± 0.52 for one of the new sequences following irradiation. Alteration of spacing (from six to 18 nucleotides) between elements had little effect, as did the addition of an adjacent Sp1 binding site. Combining the optimum number and sequence of CArG elements in an additional enhancer was found to produce the best IR induction levels. Furthermore, the improved enhancers also performed better than the previously reported prototype when used in in vitro and in vivo experimental GDEPT. We envisage such enhancers will be used to drive suicide gene expression from vectors delivered to a tumor within an irradiated field. The modest, but tight expression described in the present study could be amplified using a molecular ‘switch’ system as previously described using Cre/LoxP. In combination with targeted delivery, this strategy has great potential for significantly improving the efficacy of cancer treatment in the large number of cases where radiotherapy is currently employed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements Proc Natl Acad Sci USA 1992 89: 10149–10153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells Cancer Res 1994 54: 4266–4269

    CAS  PubMed  Google Scholar 

  3. Joki T, Nakamura M, Ohno T . Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir Hum Gene Ther 1995 6: 1507–1513

    Article  CAS  PubMed  Google Scholar 

  4. Worthington J et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter Gene Therapy 2000 7: 1126–1131

    Article  CAS  PubMed  Google Scholar 

  5. Nuyts S et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation Gene Therapy 2001 8: 1197–1201

    Article  CAS  PubMed  Google Scholar 

  6. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy Gene Therapy 2000 7: 511–517

    Article  CAS  PubMed  Google Scholar 

  7. Treisman R . The SRE: a growth factor responsive transcriptional regulator Semin Cancer Biol 1990 1: 47–58

    CAS  PubMed  Google Scholar 

  8. Christy B, Nathans D . Functional serum response elements upstream of the growth factor-inducible gene zif268 Mol Cell Biol 1989 9: 4889–4895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shaw PE, Schroter H, Nordheim A . The ability of a ternary complex to form over the serum response element correlates with serum inducibility of the human c-fos promoter Cell 1989 56: 563–572

    Article  CAS  PubMed  Google Scholar 

  10. Dalton S, Treisman R . Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element Cell 1992 68: 597–612

    Article  CAS  PubMed  Google Scholar 

  11. Hill CS et al. Functional analysis of a growth factor-responsive transcription factor complex Cell 1993 73: 395–406

    Article  CAS  PubMed  Google Scholar 

  12. Lim CP, Jain N, Cao X . Stress-induced immediate–early gene, egr-1, involves activation of p38/JNK1 Oncogene 1998 16: 2915–2926

    Article  CAS  PubMed  Google Scholar 

  13. Meyer RG, Kupper JH, Kandolf R, Rodemann HP . Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro Eur J Biochem 2002 269: 337–346

    Article  CAS  PubMed  Google Scholar 

  14. Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation Nat Med 1995 1: 786–791

    Article  CAS  PubMed  Google Scholar 

  15. Seung LP et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents Cancer Res 1995 55: 5561–5565

    CAS  PubMed  Google Scholar 

  16. Staba MJ et al. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft Gene Therapy 1998 5: 293–300

    Article  CAS  PubMed  Google Scholar 

  17. Kawashita Y et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation Hum Gene Ther 1999 10: 1509–1519

    Article  CAS  PubMed  Google Scholar 

  18. Sakamoto KM . 5’ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8 Oncogene 1991 6: 867–871

    CAS  PubMed  Google Scholar 

  19. Spencer JA, Misra RP . Expression of the serum response factor gene is regulated by serum response factor binding sites J Biol Chem 1996 271: 16535–16543

    Article  CAS  PubMed  Google Scholar 

  20. Schwachtgen JL, Campbell CJ, Braddock M . Full promoter sequence of human early growth response factor-1 (Egr-1): demonstration of a fifth functional serum response element DNA Seq 2000 10: 429–432

    Article  CAS  PubMed  Google Scholar 

  21. Prywes R, Roeder RG . Purification of the c-fos enhancer-binding protein Mol Cell Biol 1987 7: 3482–3489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Spencer JA, Misra RP . Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated- mechanism in response to serum growth signals Oncogene 1999 18: 7319–7327

    Article  CAS  PubMed  Google Scholar 

  23. Kokoris MS, Sabo P, Adman ET, Black ME . Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant Gene Therapy 1999 6: 1415–1426

    Article  CAS  PubMed  Google Scholar 

  24. Datta R et al. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation Proc Natl Acad Sci USA 1993 90: 2419–2422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Treisman R . Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors Cell 1986 46: 567–574

    Article  CAS  PubMed  Google Scholar 

  26. Pellegrini L, Tan S, Richmond TJ . Structure of serum response factor core bound to DNA Nature 1995 376: 490–498

    Article  CAS  PubMed  Google Scholar 

  27. Ruan H et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy Neoplasia 2001 3: 255–263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Int J Radiat Oncol Biol Phys 1998 42: 913–916

    Article  CAS  PubMed  Google Scholar 

  29. Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Greco O et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002 (in press).

  30. Pollock R, Treisman R . A sensitive method for the determination of protein-DNA binding specificities Nucleic Acids Res 1990 18: 6197–6204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Treisman R, Marais R, Wynne J . Spatial flexibility in ternary complexes between SRF and its accessory proteins EMBO J 1992 11: 4631–4640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Scott SD et al. A radiation-controlled molecular switch for use in gene therapy of cancer Gene Therapy 2000 7: 1121–1125

    Article  CAS  PubMed  Google Scholar 

  33. Kjellen E et al. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments Radiother Oncol 1991 22: 81–91

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The work described in this study was initiated at the Gray Cancer Institute, Northwood, Middlesex, UK, while funded by the Gray Laboratory Cancer Research Trust and the Cancer Research Campaign (CRC project grants SP2490/0101 and SP2500/0101). The authors would also like to thank Mrs Sara Bourne, Ms Amanda Walker, Mr Peter Boulton and Mrs Barbara Joiner for their excellent technical support.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, S., Joiner, M. & Marples, B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 9, 1396–1402 (2002). https://doi.org/10.1038/sj.gt.3301822

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301822

Keywords

This article is cited by

Search

Quick links